Alternative Names for the AUTOIMA Test
The AUTOIMA test is most commonly referred to as IA-2A (insulinoma-associated antigen-2 autoantibodies) or IA-2 autoantibodies, and may also be called anti-IA-2 antibodies or insulinoma-associated protein tyrosine phosphatase 2 autoantibodies. 1
Primary Nomenclature
IA-2A is the standard abbreviation used in clinical practice and diabetes guidelines for autoantibodies directed against insulinoma-associated antigen-2 1
The test detects autoantibodies to the insulinoma-associated protein tyrosine phosphatase 2, which is the full molecular name of the target antigen 2
Some laboratories may report this as anti-IA-2 antibodies or simply IA-2 autoantibodies 3, 4
Technical Variants and Specifications
When referring to the specific portion of the antigen used in testing, laboratories may specify IA-2ic (the intracytoplasmic domain of IA-2), particularly in technical or research contexts 2, 4
The test may be described by methodology: IA-2A-RIA (radioimmunoassay) or IA-2A-ELISA (enzyme-linked immunosorbent assay), depending on the detection method used 5
Clinical Context
IA-2A is classified as one of the five major islet autoantibodies used in type 1 diabetes diagnosis and prediction, alongside IAA, GADA, ZnT8A, and ICA 1, 3
In diabetes care guidelines, this test is consistently referred to as IA-2A when discussed as part of the autoantibody panel for type 1 diabetes classification 1
The abbreviation IA-2 alone may refer to either the antigen itself or the autoantibody test, with context determining the specific meaning 6, 5